{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Acadia Realty Trust"},"Symbol":{"label":"Symbol","value":"AKR"},"Address":{"label":"Address","value":"411 THEODORE FREMD AVENUE,SUITE 300, RYE, New York, 10580, United States"},"Phone":{"label":"Phone","value":"+1 914 288-8100"},"Industry":{"label":"Industry","value":"Real Estate Investment Trusts"},"Sector":{"label":"Sector","value":"Real Estate"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology."},"CompanyUrl":{"label":"Company Url","value":"https://www.acadiarealty.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Rodriguez","title":"Vice President-Information Technology"},{"name":"Kenneth F. Bernstein","title":"President, Chief Executive Officer & Trustee"},{"name":"Reginald Livingston","title":"Chief Investment Officer & Executive VP"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}